Cancer Vaccine

Promising therapeutic approaches to vaccination for cancer reviewed

Published in Cancer Vaccine Week, September 5th, 2005

Researchers review promising therapeutic approaches to vaccination for malignant disease in a recent issue of The Surgeon.

According to a study from England, "Immunotherapy of cancer is now entering its second century. Much of our understanding of the complex interaction between tumors and the host immune system has come about because of technological and immunobiological advances in very recent years."

"For some malignancies, such as bladder cancer and malignant melanoma, immunotherapy is becoming an accepted form of adjuvant therapy," said A. McKechnie and colleagues at the University of Nottingham. "However, for most types of cancer,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Vaccine Week

Source: Cancer Vaccine Week (2005-09-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry